Recce Ltd has released a press release.
Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Notice of Special General Meeting/Proxy Form
- Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
- Successful Completion of Share Purchase Plan
- Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel
- US Department of Defense Grants US $2m for R327G
Later from Recce Pharmaceuticals
- Efficacy Data & Approval to Continue Ph II ABSSSI Trial
- Phase II ABSSSI Clinical Trial Advances to Final Stages
- AGM Presentation
- Ethics Approval for Registrational Ph3 R327G Clinical Trial
- AUD $6.75m R&D Rebate Approved
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals